What diseases and symptoms does Ibrutinib/Yike Capsule mainly treat?

Ibrutinib/Ibrutinib (Ibrutinib) is an oral BTK inhibitor that inhibits abnormal B cell proliferation by targeting key kinases in the B cell receptor signaling pathway. Its main indications include chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia and some treatment-refractory B-cell non-Hodgkin's lymphoma. For these diseases, ibrutinib can improve symptom control, delay disease progression, and improve patients' quality of life.

In patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, ibrutinib can effectively reduce the accumulation of abnormalB cells, alleviate symptoms such as lymphadenopathy, splenomegaly and abnormal blood indicators, and improve anemia, infection risk and bleeding tendency. For patients with mantle cell lymphoma, ibrutinib can help control tumor cell proliferation, delay disease progression, and improve systemic symptoms, such as fatigue, night sweats, weight loss, etc.

Ibrutinib also shows good efficacy in Waldenstrom's macroglobulinemia. By inhibiting the level of immunoglobulin M (IgM) secreted by abnormalB cells, Ibrutinib improves blood viscosity symptoms and reduces the risk of complications caused by high peripheral blood viscosity. During treatment, the patient's systemic symptoms, lymph node volume, and laboratory indicators need to be monitored regularly to evaluate drug efficacy and adjust dosage.

In addition, ibrutinib has the advantages of oral convenience and long-term maintenance treatment in clinical practice. Compared with traditional chemotherapy, it has milder immunosuppressive and myelosuppressive side effects, providing a more comfortable treatment experience for long-term disease management. Patients need to maintain regular medication and follow-up during the medication process, and at the same time understand the possible adverse reactions of the medication to ensure that the treatment is safe and effective.

Reference materials:https://www.imbruvica.com/